Lv7
3760 积分 2020-09-23 加入
PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL)
2年前
已关闭
Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors
2年前
已完结
Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma
2年前
已完结
Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma
2年前
已完结
Advances in Diagnosis and Management of Diffuse Large B-cell Lymphoma
2年前
已完结
Successful experience of treatment of a patient with generalized non-GCB- DLBCL using the R-mNHL-BFM-90 protocol with lenalidomide: case report and review of literature
2年前
已完结
Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis
2年前
已完结
皖公网安备34019202002308
